 UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX, a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration FDA has granted orphan drug designation ODD for the companys CD1d targeted Gammabody TM , LAVA-051, for the treatment of chronic lymphocytic leukemia CLL. CLL is a form of leukemia characterized by progressive accumulation of abnormal lymphocytes in the peripheral blood, bone marrow and lymphoid tissues. 